Quarterly report pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of identifiable assets acquired and liabilities assumed (Details)

v3.23.1
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of identifiable assets acquired and liabilities assumed (Details) - USD ($)
Mar. 31, 2023
Feb. 21, 2023
Dec. 31, 2022
Apr. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Business Combination, Separately Recognized Transactions [Line Items]            
Goodwill $ 12,004,000   $ 8,079,000   $ 2,068,000 $ 2,068,000
Kind Therapeutics USA LLC.            
Business Combination, Separately Recognized Transactions [Line Items]            
Current assets, net of cash acquired       $ 5,047,000    
Property and equipment       622,000    
Goodwill       6,011,000    
Current liabilities       (511,000)    
Fair value of net assets acquired       17,952,000    
Kind Therapeutics USA LLC. | Tradename and trademarks            
Business Combination, Separately Recognized Transactions [Line Items]            
Intangible assets:       2,041,000    
Kind Therapeutics USA LLC. | Licenses and customer base            
Business Combination, Separately Recognized Transactions [Line Items]            
Intangible assets:       4,700,000    
Kind Therapeutics USA LLC. | Non-compete agreements            
Business Combination, Separately Recognized Transactions [Line Items]            
Intangible assets:       $ 42,000    
Ermont Acquisition            
Business Combination, Separately Recognized Transactions [Line Items]            
Property and equipment   $ 800,000        
Goodwill   3,925,000        
Fair value of net assets acquired   10,558,000        
Ermont Acquisition | Tradename and trademarks            
Business Combination, Separately Recognized Transactions [Line Items]            
Intangible assets:   1,060,000        
Ermont Acquisition | Licenses and customer base            
Business Combination, Separately Recognized Transactions [Line Items]            
Intangible assets:   $ 4,773,000